Drug Type Antibody |
Synonyms |
Target |
Action inhibitors |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | Thailand | 30 Nov 2022 | |
Lung Cancer | Preclinical | Thailand | 30 Nov 2022 | |
Transitional Cell Carcinoma | Preclinical | Thailand | 30 Nov 2022 |